A Double-Blind Trial Comparing Antiemetic Efficacy and Toxicity of Metoclopramide Versus Methylprednisolone Versus Domperidone in Patients Receiving Doxorubicin Chemotherapy Alone or in Combination with Other Antiblastic Agents
Authors:
- Fausto RoilaFRFausto Roila
- Sergio BracardaSBSergio Bracarda
- Maurizio TonatoMTMaurizio Tonato
- Enzo BallatoriEBEnzo Ballatori
- Albano Del FaveroAFAlbano Del Favero
- 1 October 1988
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 11 (5) , 594-596
Abstract
Nausea and vomiting are reported in approximately 60% of neoplastic patients treated with doxorubicin used alone at doses greater than or equal to 50 mg/m2 or in combination with other noncisplatin antiblastic agents. In a double-blind study we compared the efficacy and tolerability of metoclopramide (MTC) versus Domperidone (DMP) versus methylprednisolone (MP) administered intravenously (i.v.) to inpatients. Forty-four patients entered the trial. The three antiemetic regimens were found equally effective. A complete protection from vomiting/nausea was obtained in 14/11 (93.3%/73.3%) of patients treated with MTC, in 15/14 (100%/93%) of those treated with MP and in 11/11 (78.6%/78.6%) of those treated with DMP. Side effects were slight and not significantly different among the three regimens. In conclusion, i.v. MTC and MP (DMP is no longer available in i.v. formulation) as single agents are an adequate treatment for prevention of nausea and vomiting induced by doxorubicin alone or in combination with other noncisplatin antiblastic agents.Keywords
This publication has 4 references indexed in Scilit:
- High-Dose Oral and Intravenous Metoclopramide in Doxorubicin/Cyclophosphamide-Induced Emesis A Randomized Double-Blind StudyAmerican Journal of Clinical Oncology, 1987
- Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1987
- A pilot study of high-dose domperidone as an antiemetic in patients treated with cisplatinEuropean Journal of Cancer and Clinical Oncology, 1985
- Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over studyEuropean Journal of Cancer and Clinical Oncology, 1984